Passle Menu Joel Sandler November 19, 2021 1 56 TCR T-cell Therapies: What if Magic Bullets Simply Aren't Good Enough? On the heels of a recent post in which I discussed evolving dynamics and strategic implications underscoring different types of... Read More… Joel Sandler November 11, 2021 1 136 Donor-derived T-cells vs. iPSC- and Cord-derived NKs: Allo Not Created Equal A common question I get from my cancer cell therapy clients at Cello Health BioConsulting is why, despite the lion share of clinical data... Read More… Jane Barrett October 27, 2021 1 58 Different perspectives on the Burden of Disease What do medical market research and health economic outcomes research have in common? How can we combine our work on burden of disease in... Read More… Mike Rice, Beth Fordham-Meier, Andrew Ng August 24, 2021 Are We Nearing the Plateau of Productivity for in-vivo Therapeutic Gene Editing? Amidst success of in vivo adeno-associated virus (AAV) based gene therapies, the gene therapy community awaits key outcomes from next... Read More… James Lee August 19, 2021 34 Evolution of the New Decade of China Biopharma: Investing in the Future and Thinking Globally The recent Chinese biopharma boom has been driven by six main factors: 1) Abundance of capital (government subsidies/funding, private... Read More… Jeff Bockman July 29, 2021 62 Precision vs Imprecision Oncology I got to thinking recently about the push towards developing drugs for molecularly stratified patient populations, including a spate of... Read More… Ginger Johnson July 8, 2021 92 Silver Lining to Approval of Aducanumab? The accelerated and broad label approval of Biogen’s Alzheimer's Disease (AD) drug aducanumab (Aduhelm) is controversial (to say the... Read More… Jeff Bockman, Joel Sandler April 29, 2021 32 Next Wave AntiCancer Therapies Part 1 “In 1890, the Russian playwright and physician Anton Chekov wrote a letter in which he alluded to a centuries-old observation that... Read More… Rob Stringer April 16, 2021 39 Pharma perspective: Does the patient journey inform better strategy and enhance patient outcomes? Q&A with Pharma Progress 2021 panellist: Daniel De Schryver, Patient Engagement & Advocacy Lead, Europe, Middle-East and Africa,... Read More… Giovanni Ciavarra, Joel Sandler April 6, 2021 42 Anticancer Cellular Immunotherapies: Optimizing the Path from Bench to FDA Approval A striking number of anticancer cellular immunotherapies, also commonly referred to as adoptive cellular therapies (ACT), are in various... Read More… Keep in touch @cellohealth /cello-health /cello-health-talent @hello_cello_us Contact us Privacy policy Cello Health plc Covid-19 Commitment COOKIE CONTROL Some of these cookies are essential, while others help us to improve your experience by providing insights into how the site is being used, including - in some instances - sharing data with other customers. You can use this tool to change your cookie settings. Otherwise, we’ll assume you’re OK to continue. I'm fine with this More details